One possible approach to combine ICI and EGFR TKI therapy more safely would be to target treatments specifically to tumor cells, for example by tumor-homing nanoparticles (134), thereby bypassing adverse effects due to systemic impact of the drugs. This evidence concerns the gene EGFR and neoplasm.